

MICROBIOLOGY DX, INC.

19A CROSBY DRIVE, STE 215
BEDFORD, MA 01730

TEL: (781) 276-4956 * FAX: (781) 275-6236

DR. J.D. MUSTO, DAB
PRESIDENT & LAB DIRECTOR
CLIA ID# 22D2089996

LABORATORY
REPORT

PATIENT:	BIRD, DAVID 21 BURWOOD ROAD HAWTHORN, VIC 3122 AUSTRALIA	CLIENT:	DR. DAVID BIRD NIIM MELBOURNE, VIC, 3122, AU 600565
D.O.B./SEX:	██████████ 1965 ████████ M	DOCTOR:	D BIRD
DATE COLLECTED:	06/13/2017	DATE REPORTED:	06/27/2017 12:45
TIME COLLECTED:		DATE PRINTED:	06/28/2017
LAB NUMBER:	14125960	PATIENT ID:	

PAGE: 1

** FINAL REPORT **

** FINAL REPORT **

RESULTS

NARES CULTURE

SOURCE

ORGANISM ##1

NARES
NO STAPH COAG NEGATIVE ISOLATED
NON-MARCONS
-

MARCONS is a multiple antibiotic resistant coag neg staph that reside in the deep nasal passages, is common in biotoxin illness, is a marker of low MSH and produce biofilms which form a barrier to immune defenses and anti-infection therapy. Biofilm production in bacteria, mold or yeast may account for some cases of chronic nasal and sinus congestion and inflammation. MARCONS releases exotoxins which lead to increased inflammation (decreased MSH) and hemolysins which disrupt RBCs and endothelial cells. It may be colonized or cause infection. If test results indicate coag neg staph is present with two or more antibiotics showing Resistant or Intermediate, these results are classified as MARCONS whether Methicillin is resistant or not and whether there is a large amount or small amount. (Ref: Dr. Ritchie Shoemaker, 05/09/14)

ORGANISM ##2

KLEBSIELLA PNEUMONIAE-LARGE AMOUNT

SUSCEPTIBILITY ##2

GRAM NEGATIVE ENTERIC RODS
SUSCEPTIBILITY
ANTIBIOTIC NAME INTERPRETATION
AMIKACIN S
AMPICILLIN R
CEFAZOLIN R
CEFEPIME S
CEFOXITIN R
CEFTAZIDIME S
CEFTRIAKONE S
CIPROFLOXACIN S
ERTAPENEM S
GENTAMICIN S
IMIPENEM S
LEVOFLOXACIN S
PIPERACILLIN/TAZOBACTAMS
TIGECYCLINE S
TRIMETH/SULFA (BACTRIM) S

ORGANISM ##3

CORYNEBACTERIUM SPS.-MOD AMOUNT
NO DEFINITIVE GUIDELINE FOR SUSCEPTIBILITY. MOST SPECIES ARE SUSCEPTIBLE TO VANCOMYCIN, DOXYCYCLINE, CIPROFLOXACIN, AMPICILLIN, CEPHALOTHIN, CEFUROXIME, IMIPENEM, ERYTHROMYCIN, AZITHROMYCIN, CLINDAMYCIN AND GENTAMYCIN.

** FINAL REPORT **